Roche disclosed more details on its Axelios 1 sequencing platform at AGBT, including a claimed consumable cost equating to $150 per 30X human genome in duplex mode. Roche provided workflow and throughput metrics and said pre‑orders will open after the meeting, with formal launch slated for summer. The company highlighted early use cases in cancer genomics and methylation mapping. Roche’s pricing brings Axelios into direct competition with other new entrants and established players that have recently announced sub‑$200 genome claims; Roche executives framed the list price as reflective of expected real‑world yields. The announcement included instrument list price context and performance claims but industry observers note independent validation and throughput in customers’ hands will determine comparative value.